Authors
Latest:
Reviewing the Latest Advancements in Treatment of TNBCLisa A. Carey, MD, ScM, discusses the recent trends in treatment for triple-negative breast cancer.
Latest:
US-Cuban Partnership Developing Anticancer Vaccine for NSCLCLeaders of Roswell Park Cancer Institute (RPCI) in Buffalo, New York, have agreed to collaborate with the Center for Molecular Immunology (CIM) in Cuba to evaluate a therapeutic anticancer vaccine for non–small cell lung cancer (NSCLC) in the United States.
Latest:
Exploring the Efficacy of Pembrolizumab in Sarcoma SubtypesLisa H. Butterfield, PhD, professor of medicine, surgery, and immunology, director, University of Pittsburgh Immunologic Monitoring and Cellular Products Laboratory, and president of the Society for Immunotherapy of Cancer, discusses the SARC028 study, which explored the efficacy of pembrolizumab (Keytruda) in advanced soft tissue and bone sarcomas.
Latest:
Expanded Guidelines Offer Clearer Diagnosis for Classical, Special Variants of CMMLRecent guidelines highlight the need to distinguish chronic myelomonocytic leukemia from conditions similar to other myeloproliferative neoplasms, provide standardized diagnostic procedures, and outline therapeutic options for adult patients with CMML.
Latest:
Debating the True Benefit of Adjuvant TKIs in High-Risk RCCAdjuvant therapy with TKIs for patients with high-risk renal cell carcinoma who have undergone a nephrectomy may be supported by level IIa evidence from the National Comprehensive Cancer Network guidelines, yet this approach is still controversial, with many physicians believing that there are not yet enough data in support of its use.
Latest:
Tumor Antigens and Their Role in Immune Response in MelanomaMelanoma is the most deadly skin cancer. According to data collected between 2004 and 2010, only 16% of Americans with metastatic melanoma, including people of all ages and races, and both genders, survive for 5 years or more after diagnosis.
Latest:
The myPath Test for MelanomaLoren Clarke, MD, vice president of Medical Affairs of Dermatology at Myriad Genetics, discusses the company’s new myPath test for melanoma
Latest:
A Flood of Bispecific Antibodies Anticipated in Multiple MyelomaOne of the most promising innovations in the multiple myeloma space has been the development of bispecific antibodies.
Latest:
Studies of CAR T Cells for B-Cell MalignanciesLori Leslie, MD, discusses ongoing clinical trials that are exploring chimeric antigen receptor T-cell therapy for the treatment of B-cell malignancies.
Latest:
Endocrine Resistance Therapy in Early-Stage Breast CancerLori Goldstein, MD, director, The Naomi and Phil Lippincott Breast Evaluation Center, deputy associate director, Clinical Research, Fox Chase Cancer Center, discusses the possibility of using endocrine resistance therapy to treat patients with early stage breast cancer.
Latest:
Clinical Insights for Treating RAI-Refractory DTCLori J. Wirth, MD, offers advice to oncologists using lenvatinib when treating patients with differentiated thyroid cancer.
Latest:
Hopes for Brexucabtagene Autoleucel in Mantle Cell LymphomaLori Leslie, MD, describes the cohorts of the phase 2 ZUMA-2 study and discusses the potential impact of brexucabtagene autoleucel in the mantle cell lymphoma landscape.
Latest:
Chronic Lymphocytic Leukemia Treatment Evolving With Some ChallengesWhere once limited treatment options existed for patients with CLL, medical oncologists now have a plethora of agents from which to choose, making disease management in CLL more effective with fewer toxicities.
Latest:
Oncolytic Vaccines With Chemotherapy Show Survival Benefit in Head and Neck CancerThe attenuated vaccinia virus, GL-ONC1, demonstrated safety and clinical benefit when delivered intravenously with concurrent chemoradiation therapy in patients who have locoregionally advanced head and neck carcinoma (LA-HNC).
Latest:
Dr. Lorraine Pelosof on the Growing Proportions of Non-Smokers With NSCLCLorraine Pelosof, MD, PhD, assistant professor of Hematology and Oncology, UT Southwestern Medical Center, on the increasing proportion of non-smokers developing non-small cell lung cancer (NSCLC).
Latest:
Dr. Louis Harrison on Immunotherapy and Radiation Therapy CombinationsLouis B. Harrison, discusses the recent opportunities to combine radiation therapy and immunotherapy.
Latest:
Dr. Lowell Anthony: Use of Telotristat Etiprate in Patients With Carcinoid SyndromeLowell B. Anthony, MD, professor of Medicine, University of Kentucky, what community oncologists can take away from the phase III placebo-controlled TELESTAR trial, which evaluated telotristat etiprate in patients with inadequately controlled carcinoid syndrome.
Latest:
EP. 4B: Considering Chemotherapy-Induced Myelosuppression and the Impact of Trilaciclib on Its ManagementIn this companion article, Dr. Lowell L. Hart shares key insights into how trilaciclib has begun to impact the management of chemotherapy-induced myelosuppression in patients with SCLC.
Latest:
Masarova on the Latest Updates Across Myeloproliferative NeoplasmsLucia Masarova, MD, PhD, discusses some of the latest updates across myeloproliferative neoplasms.
Latest:
The Current and Future Role of Immunotherapy in MesotheliomaLuciano Mutti, PhD, professor in cancer research, University of Salford, Manchester, discusses the current and future role of immunotherapy in mesothelioma.
Latest:
Dr. Luciano Rossetti on the Function of Anti-PD-L1 Treatments in Bladder CancerLuciano Rossetti, MD, head of Global Scientific Strategy, Merck Research Laboratories, talks about the discovery of PD-L1 and how the finding has evolved into potential treatments for bladder cancer patients, specifically avelumab.
Latest:
Diaz Discusses the FDA Approval of Pembrolizumab for MSI-H Solid TumorsLuis A. Diaz Jr, MD, head, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, discusses the recent FDA approval of pembrolizumab (Keytruda) for microsatellite instability-high (MSI-H) colorectal cancer and other tumor types.
Latest:
PD-1 Blockade in Mismatch Repair Deficiency in CRCLuis Alberto Diaz, Jr, MD, associate professor of Oncology, Johns Hopkins University, discusses PD-1 blockade in mismatch repair deficiency in colorectal cancer (CRC).
Latest:
EP 12B: Management of Chemotherapy Induced Myelosuppression (CIM) in ES-SCLCIn this companion article, Dr Luis Raez provides insights into effective management patients with extensive-stage small cell lung cancer who develop chemotherapy-induced myelosuppression.
Latest:
ARAF as a New Driver in Lung AdenocarcinomaLuiz H. Araujo, MD, medical oncologist, Corporate Cancer Foundation fellow, Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, discusses the discovery of oncogenic ARAF as a new driver for lung cancer.
Latest:
An Overview of the ALSYMPCA Study in Metastatic Prostate CancerLuke Nordquist, MD, FACP, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, gives an overview of the Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) study, and he discusses ongoing trials examining the use of radium-223 dichloride (Xofigo) in metastatic castration-resistant prostate cancer (mCRPC).
